Advertisement

ADVERTISEMENT

CLL/MCL

Dr Lokhande
Videos
Study Profiles T-Cell Subpopulations Based on Spatial Proteome in MCL
04/18/2022
Lavanya Lokhande, PhD, discusses results from a study, presented at the AACR Annual Meeting, which investigated T-cell subpopulations profiled by spatial proteome among patients with MCL.
Lavanya Lokhande, PhD, discusses results from a study, presented at the AACR Annual Meeting, which investigated T-cell subpopulations profiled by spatial proteome among patients with MCL.
Lavanya Lokhande, PhD, discusses...
04/18/2022
Oncology
Gaël Roué, PhD
Videos
Loss of GTPase RhoA Impairs Lenalidomide Activity in MCL
04/18/2022
Gaël Roué, PhD, highlights a study providing insight into how the loss of the small GTPase RhoA enhances lymphomagenesis and impairs the activity of lenalidomide in patients with MCL.
Gaël Roué, PhD, highlights a study providing insight into how the loss of the small GTPase RhoA enhances lymphomagenesis and impairs the activity of lenalidomide in patients with MCL.
Gaël Roué, PhD, highlights a...
04/18/2022
Oncology
Dr Rodrigues
Videos
Impact of CD163-Positive Cells on MCL Development and Treatment Response
04/13/2022
A study presented at the AACR Annual Meeting demonstrates that spatial localization within the MCL tumor affects the expression of CD163-positive macrophages and identifies possible targetable markers.
A study presented at the AACR Annual Meeting demonstrates that spatial localization within the MCL tumor affects the expression of CD163-positive macrophages and identifies possible targetable markers.
A study presented at the AACR...
04/13/2022
Oncology
Dr Aroldi
Videos
Dr Aroldi Overviews CD24 ‘Don’t Eat Me’ Signal as a Potential Immunotherapeutic Target for MCL
03/29/2022
Andrea Aroldi, MD, overviews the CD24 ‘don’t eat me’ signal immune checkpoint blockade as a potential immunotherapeutic target for MCL, presented at ASH 2021.
Andrea Aroldi, MD, overviews the CD24 ‘don’t eat me’ signal immune checkpoint blockade as a potential immunotherapeutic target for MCL, presented at ASH 2021.
Andrea Aroldi, MD, overviews the...
03/29/2022
Oncology
Anita Kumar, MD
Videos
Dr Kumar Highlights Safety, Efficacy of Obinutuzumab-Based Triplet Regimen for TP35-Mutant MCL
02/04/2022
Anita Kumar, MD, highlights preliminary safety and efficacy data from a phase 2 study on zanubrutinib, obinutuzumab, and venetoclax for untreated patients with MCL expressing a TP53 mutation.
Anita Kumar, MD, highlights preliminary safety and efficacy data from a phase 2 study on zanubrutinib, obinutuzumab, and venetoclax for untreated patients with MCL expressing a TP53 mutation.
Anita Kumar, MD, highlights...
02/04/2022
Oncology
Dr Phillips
Videos
Glofitamab Step-Up Dosing Induces High Response Rates in MCL
01/19/2022
Tycel Phillips, MD, highlights how glofitamab step-up dosing induces high response rates in patients with R/R MCL that didn't respond to BTKi therapy. These data were presented at ASH 2021.
Tycel Phillips, MD, highlights how glofitamab step-up dosing induces high response rates in patients with R/R MCL that didn't respond to BTKi therapy. These data were presented at ASH 2021.
Tycel Phillips, MD, highlights...
01/19/2022
Oncology
Dr Shadman
Videos
Dr Shadman Discusses Safety and Efficacy of Third Generation CD20 Targeted CAR-T for R/R B-NHL, CLL
01/10/2022
Mayzar Shadman, MD, MPH, discusses the safety and efficacy of a third-generation CD20-targeted CAR-T therapy for relapsed/refractory B-NHL and CLL, presented at ASH 2021.
Mayzar Shadman, MD, MPH, discusses the safety and efficacy of a third-generation CD20-targeted CAR-T therapy for relapsed/refractory B-NHL and CLL, presented at ASH 2021.
Mayzar Shadman, MD, MPH,...
01/10/2022
Oncology
medical
Test Your Knowledge
Quiz: Does Cirmtuzumab Plus Ibrutinib Demonstrate Clinical Benefit in MCL, CLL?
12/20/2021
True or false: Results from a phase 1b and 2 study found cirmtuzumab plus ibrutinib was not well tolerated in patients with R/R MCL or CLL.
True or false: Results from a phase 1b and 2 study found cirmtuzumab plus ibrutinib was not well tolerated in patients with R/R MCL or CLL.
True or false: Results from a...
12/20/2021
Oncology
News
Cirmtuzumab Plus Ibrutinib Demonstrates Clinical Benefit in MCL, CLL
12/20/2021
Phase 1b and 2 results of cirmtuzumab plus ibrutinib in patients with MCL or CLL were shared at the 2021 ASH Annual Meeting.
Phase 1b and 2 results of cirmtuzumab plus ibrutinib in patients with MCL or CLL were shared at the 2021 ASH Annual Meeting.
Phase 1b and 2 results of...
12/20/2021
Oncology
Dr G
Videos
Ibrutinib Plus Venetoclax Yields Deep Responses in Patients With CLL
12/16/2021
Paolo Ghia, MD, PhD, discusses 2-year follow-up results from the phase 2 CAPTIVATE study on first-line ibrutinib plus venetoclax for the treatment of patients with CLL. These data were presented at the 2021 ASH Annual Meeting.
Paolo Ghia, MD, PhD, discusses 2-year follow-up results from the phase 2 CAPTIVATE study on first-line ibrutinib plus venetoclax for the treatment of patients with CLL. These data were presented at the 2021 ASH Annual Meeting.
Paolo Ghia, MD, PhD, discusses...
12/16/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 18 ⁠–⁠ September 20
September 20 ⁠–⁠ September 22
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use